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CONCLUSIONS AND IMPLICATIONS FOR POLICY-MAKING
The results indicate that initiation of therapy with sildenafil in patients with functional class II PAH and functional class III PAH would result in probable cost-savings compared with other PAH therapies. This is an important finding, as the costs associated with therapies for PAH are considerable. These findings also do not support differential funding of PAH therapies for patients with functional class II versus functional class III disease. It would seem appropriate, based not only on clinical trial evidence but also with respect to cost-effectiveness, to initiate therapy with sildenafil provided it is not contraindicated.
With respect to add-on combination therapy for PAH, unfortunately there were no comparisons examining the addition of treatments to either sildenafil or tadalafil; however, studies have examined the addition of tadalafil and riociguat to existing ERA therapy. ERA monotherapy was the most cost-effective strategy versus the combination therapy. Considering that ERA monotherapy was not cost-effective compared with either sildenafil or supportive care, it is challenging to draw conclusions from this analysis.
BACKGROUND
Pulmonary arterial hypertension (PAH) is a chronic progressive condition characterized by increased pulmonary vascular resistance that often leads to right ventricular heart failure and death. PAH not only shortens affected individuals' lives, but also significantly impacts their quality of life, limiting their ability to work and perform day-to-day activities, and often leading to social isolation.
The choice of oral therapy for initiation of treatment is challenging, as there are very few head-to-head clinical trials from which to assess the comparative effectiveness of PAH drugs. In patients who do not adequately respond to monotherapy (i.e., a single advanced therapy drug treatment), sequential addition of a second drug is usually recommended by PAH specialists in Canada.
As new drug therapies emerge, their comparative effectiveness must be considered, from both clinical and economic perspectives. Both monotherapy and combination therapy regimens should be examined.
OBJECTIVES
To assess the cost-effectiveness of monotherapy with a phosphodiesterase-5 (PDE-5) inhibitor, an endothelin receptor antagonist (ERA), or a prostanoid versus supportive care in patients with PAH, and to assess the cost-effectiveness of add-on combination therapy versus monotherapy PAH drugs. Extensive sensitivity analyses found the results to be robust to changes in most model assumptions. In the probabilistic sensitivity analysis, sildenafil was the most cost-effective therapy in the majority of replications at willingness-to-pay values from $0 to $200,000 per QALY in both functional class II PAH and functional class III PAH. Tadalafil was the only other therapy that had greater than 0% chance of being cost-effective; however, the probability for tadalafil ranged only between 20% and 30% of replications.
Add-on Combination Therapy Versus Monotherapy
There were no studies comparing monotherapy with a PDE-5 inhibitor to add-on therapy. At a decision-maker's willingness to pay of less than ~$88,000 per QALY, neither add-on therapy with an ERA plus tadalafil nor add-on therapy with an ERA plus riociguat would be considered cost-effective in patients with PAH in functional class II and III relative to an ERA alone (Table 2) .
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